T1	p 65 88	severe bronchiectasis .
T2	p 156 170	bronchiectasis
T3	p 251 270	in bronchiectasis .
T4	p 416 489	bronchiectasis . Twenty-four patients ( 12 female ; mean age 51 yr ) were
T5	p 602 606	= 12
T6	p 1469 1485	bronchiectasis .
T7	i 6 25	Inhaled fluticasone
T8	i 98 120	corticosteroid therapy
T9	i 316 334	placebo-controlled
T10	i 393 412	inhaled fluticasone
T11	i 523 558	inhaled fluticasone ( 500 microgram
T12	i 565 572	daily )
T13	i 581 597	Accuhaler device
T14	i 609 621	or placebo .
T15	i 826 837	leukotriene
T16	i 979 990	fluticasone
T17	i 1007 1018	fluticasone
T18	i 1041 1048	placebo
T19	i 1247 1258	fluticasone
T20	i 1411 1434	inhaled steroid therapy
T21	o 34 61	sputum inflammatory indices
T22	o 229 250	and infective markers
T23	o 638 768	spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta
T24	o 778 821	tumor necrosis factor-alpha ( TNF-alpha ) ,
T25	o 826 837	leukotriene
T26	o 914 945	in sputum leukocyte density and
T27	o 1114 1135	changes in spirometry
T28	o 1156 1182	reported adverse reactions
T29	o 1288 1315	sputum inflammatory indices